Search company, investor...

LIDDS

liddspharma.com

Founded Year

2003

Stage

IPO | IPO

Date of IPO

7/31/2014

About LIDDS

LIDDS (Local Intelligent Drug Delivery System) is a Swedish pharmaceutical company developing innovative pharmaceutical products based on medical need and its proprietary drug delivery technology. LIDDS was initially founded by researchers and entrepreneurs at Uppsala University, departments of pharmacy and material sciences and University of Gothenburg, departments of urology and oncology, and within the life-science incubator P.U.L.S. (www.pulsinvest.se), LIDDS is located in Helsingborg, Sweden, in one of Europe's premiere biotechnology regions. Liproca Depot is the first product being developed by LIDDS based on this drug delivery technology. It is a novel product targeted primarily for the treatment of prostate cancer. The purpose is to reduce the side-effects significantly as well as to potentially increase the effect relative to other current treatment alternatives. The strategic, technological, clinical and pharmaceutical competences to support the comprehensive and focused development of Liproca Depot are contained within the unique network of LIDDS and PULS.

Headquarters Location

Kullagatan 8

Helsingborg, SE-252 20,

Sweden

+46(0)737 070922

Missing: LIDDS's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: LIDDS's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing LIDDS

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LIDDS is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

LIDDS Patents

LIDDS has filed 1 patent.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Life sciences industry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/5/2019

4/7/2020

Pharmaceutical industry, Dosage forms, Metal halides, Drug delivery devices, Life sciences industry

Grant

Application Date

6/5/2019

Grant Date

4/7/2020

Title

Related Topics

Pharmaceutical industry, Dosage forms, Metal halides, Drug delivery devices, Life sciences industry

Status

Grant

Latest LIDDS News

LIDDS Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

LIDDS Rank

LIDDS Frequently Asked Questions (FAQ)

  • When was LIDDS founded?

    LIDDS was founded in 2003.

  • Where is LIDDS's headquarters?

    LIDDS's headquarters is located at Kullagatan 8, Helsingborg.

  • What is LIDDS's latest funding round?

    LIDDS's latest funding round is IPO.

  • Who are the investors of LIDDS?

    Investors of LIDDS include P.U.L.S..

  • Who are LIDDS's competitors?

    Competitors of LIDDS include Adamas Pharmaceuticals, Esperance Pharmaceuticals, GANYMED Pharmaceuticals, Syndax Pharmaceuticals, Angstrom Pharmaceuticals and 12 more.

Compare LIDDS to Competitors

T
The DNA Repair Company

The DNA Repair Company was founded to bring recent scientific discoveries from the Dana Farber Cancer Institute and the Massachusetts Institute of Technology to the clinic to benefit cancer patients. Breakthroughs in understanding DNA repair mechanisms have led to new personalized approaches to cancer treatment, beginning with diagnostic tools that improve the efficacy of currently available cancer therapies, as well as drugs under development. DNAR exists to make these tools available to physicians with the goal of improving clinical outcomes.

C
Cobrek Pharmaceuticals

Cobrek Pharmaceuticals is engaged in the research, development and commercialization of prescription drug therapies, delivery systems and applications that improve quality of life and enhance the lifestyle of patients across the adolescent and adult age-spectrum with particular attention to the needs of the aging population.

A
Advanced Tissue Therapies

Bioceramic Therapeutics Limited is developing new kinds of material that help the body heal itself. The aim is to assist patients, especially the elderly, for whom normal tissue repair mechanisms do not result in possible medical outcomes. Such patients may have fractures or osteoporosis, need orthopedic or periodontal implants or have a condition that has damaged their bones.

M
Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

A
Activate Immunotherapy

Activate Immunotherapy (formerly NovaRx) is a clinical-stage immuno-oncology company based in San Diego, California. Activate utilizes a novel approach for activating the body's immune system to recognize and destroy cancer cells. The company's most advanced immunotherapy, Lucanix, has been tested in late stage clinical trials as a treatment for non-small cell lung cancer (NSCLC), the largest cancer indication in the world. Lucanix has promising Phase 2 and Phase 3 data. In Lucanix's Phase 2 trial, the company demonstrated a significant improvement in survival for NSCLC patients. NovaRx completed a 532 patient Phase 3 study in early 2013. While the Phase 3 study missed the statistical endpoint for approval, survival benefits were shown if non United States clinical sites were excluded, particularly with patients who started Lucanix treatment within 12 weeks of chemotherapy and/or patients with prior chemotherapy and radiation therapy. Activate's proprietary platform technology is applicable to other solid tumors.

P
Psimei Pharmaceutical

Psimei Pharmaceuticals is developing boron-based drugs for applications in Photon Activation Therapy (PAT). This involves the use of standard radiotherapy to activate boron-based compounds which selectively target solid tumours. This results in an amplification of the therapeutic effect of conventional radiotherapy. Pre-clinical data for Psimei's lead product, PP200PAT, has demonstrated 90% true cure rates at 6 months in tumour models compared with 30% for conventional radiotherapy alone. It also enabled much shorter treatment regimes - days as opposed to weeks. This drug is being prepared for clinical development.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.